Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report)'s share price traded up 0.1% during trading on Tuesday . The company traded as high as $9.25 and last traded at $9.09. 194,355 shares were traded during trading, an increase of 1,463% from the average session volume of 12,438 shares. The stock had previously closed at $9.08.
Aerovate Therapeutics Trading Up 0.1%
The business has a 50-day simple moving average of $7.92 and a 200 day simple moving average of $21.61. The stock has a market cap of $263.47 million, a P/E ratio of -3.04 and a beta of 0.95.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in AVTE. Allostery Investments LP raised its position in Aerovate Therapeutics by 67.1% during the first quarter. Allostery Investments LP now owns 1,421,568 shares of the company's stock valued at $3,568,000 after purchasing an additional 570,884 shares in the last quarter. ADAR1 Capital Management LLC raised its position in Aerovate Therapeutics by 57.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,461,234 shares of the company's stock valued at $3,668,000 after purchasing an additional 533,218 shares in the last quarter. Deltec Asset Management LLC raised its position in Aerovate Therapeutics by 86.4% during the first quarter. Deltec Asset Management LLC now owns 361,804 shares of the company's stock valued at $908,000 after purchasing an additional 167,680 shares in the last quarter. Invesco Ltd. purchased a new stake in Aerovate Therapeutics during the first quarter valued at about $187,000. Finally, Nuveen LLC purchased a new stake in Aerovate Therapeutics during the first quarter valued at about $101,000.
About Aerovate Therapeutics
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
